U.S. Markets closed

MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

·1 min read
MaxCyte, Inc
MaxCyte, Inc

ROCKVILLE, Md., Sept. 07, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13th at 4:40 p.m. Eastern Time.

A live and archived webcast of the event will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™, and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser
Gilmartin Group
David Deuchler, CFA


+1 415-937-5400
ir@maxcyte.com

Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden


+44 (0)20 7886 2500


UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh



+44 (0)203 709 5700
maxcyte@consilium-comms.com